High FDG Uptake in the Non-cancerous Lung Predicts Immune-Related Adverse Events and Poor Prognosis in Patients with Lung Cancer Treated with Immune Checkpoint Inhibitors
{{output}}
Rationale and objectives: Immune checkpoint inhibitors (ICIs) have improved survival in non-small cell lung cancer (NSCLC); however, predicting immune-related adverse events (irAEs) remains a clinical challenge. We previously sho... ...
